Development of Dendritic Cell vaccines as future treatment of patients with cancer

Completed

• Conditions: het betreft enkel afname van bloedcellen via aferese bij gezonde vrijwilligers voor verbeteren en optimaliseren productie methode cellulaire immunotherapie; NA

• Registration Number: NL-OMON55686
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Healthy volunteers, no underlying disease
Age 18 or older
Male or Female

Exclusion Criteria

no venous access

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome that is relevant:<br /><br>1. a strong T cell response in vitro with a readout of Interferon gamma<br /><br>production.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>